Medical management of benign prostatic hyperplasia (BPH) has progressed gradually in recent years and remains the starting point for most symptomatic patients seeking treatment. Beyond well-known alpha-blockers and 5-alpha reductase inhibitors, there is growing evidence for the use of phosphodiesterase-5 inhibitors and beta-3 agonists in managing the condition, which may afford additional relief of "bothersome" symptoms in some patients.
This review details contemporary medical management of BPH with an emphasis on the indications for certain classes of pharmacotherapy and their relative benefits and side effects. Surgical and procedural treatment of BPH is covered in a separate review.
Cleveland Clinic journal of medicine. 2024 Mar 01*** epublish ***
Eiftu S Haile, Ayodeji E Sotimehin, Bradley C Gill
Department of Urology, Cleveland Clinic, Cleveland, OH ., Department of Urology, Cleveland Clinic, Cleveland, OH., Department of Urology, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/38429006